Rockwell Medical (RMTI) Q1 2025 earnings summary

Executive summary

• Q1 2025 was a transition period with net sales of $18.9M, down 17% year-over-year due to the largest customer transitioning to another supplier, partially offset by a one-time $0.9M payment.

• Gross profit was $3.0M, flat year-over-year, with gross margin improving to 16% from 14%.

• Net loss improved to $1.5M from $1.7M in Q1 2024; adjusted EBITDA was negative $0.4M, impacted by seasonal expenses.

• Launched a new single-use bicarbonate cartridge, targeting growth in at-home dialysis and high-margin product segments.

• Active pursuit of business development and international expansion, especially in Latin America and the U.S. West Coast.

Financial highlights

• Net sales: $18.9M in Q1 2025 vs $22.7M in Q1 2024, a 17% decrease.

• Gross profit: $3.0M in Q1 2025, flat year-over-year; gross margin 16% vs 14%.

• Net loss: $1.5M in Q1 2025 vs $1.7M in Q1 2024; EPS $(0.04) vs $(0.06).

• Adjusted EBITDA: negative $0.4M in Q1 2025.

• Cash, cash equivalents, and investments: $17.3M as of March 31, 2025, down from $21.6M at year-end 2024.

Outlook and guidance

• 2025 guidance reiterated: net sales of $65M–$70M, gross margin of 16%–18%, and adjusted EBITDA between negative $0.5M and positive $0.5M.

• Q2 2025 expected to be the low point for revenue, with improvement anticipated in the second half.

• Revenue guidance is based on the current customer base; new customers would provide upside.

• Management believes current liquidity is sufficient for at least the next 12 months.

• Company may raise additional capital via $21.1M available under its ATM facility or other financings.